AstraZeneca Leaves Door Ajar To Pfizer, Despite Hurdles - Presented by: The Aol. On Network

AstraZeneca's boss said on Wednesday he would engage with Pfizer if the price was right and the risks posed from forcing the British drugmaker's operations into the U.S. company's new three-unit model were addressed. Chief Executive Pascal Soriot stressed his company had a bright future as a stand-alone firm but acknowledged that shareholders would expect AstraZeneca's board to negotiate if terms were sufficiently attractive in a sweetened offer.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
BAC $ 17.03 0.19 ▼ 1.10%
INTC $ 30.555 0.38 ▲ 1.24%
AAPL $ 126.44 0.16 ▼ 0.13%
XIV $ 40.59 2.71 ▼ 6.26%
MU $ 19.07 0.29 ▲ 1.54%
GE $ 26.78 0.12 ▲ 0.45%
VALE $ 5.85 0.09 ▲ 1.56%
PBR $ 8.83 0.18 ▲ 2.08%

As of 7/2/2015, 04:15 PM